Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions Inc (NASDAQ: BLFS) maintains industry leadership through innovative biopreservation solutions for cell and gene therapies. This dedicated news hub provides comprehensive updates on corporate developments, regulatory milestones, and technological advancements essential for stakeholders in the life sciences sector.
Access official press releases covering quarterly earnings, strategic partnerships, and product innovations in cryopreservation media and cold chain management systems. Our curated collection serves investors and researchers requiring timely, accurate information about BLFS's role in advancing biologic manufacturing infrastructure.
The resource prioritizes updates on BioLife's core competencies: clinical-grade cell processing tools, smart shipper technologies, and quality assurance protocols critical for therapy commercialization. Content spans regulatory filings, manufacturing expansions, and intellectual property developments shaping the biostorage industry.
For consistent monitoring of BioLife's market position, bookmark this page or subscribe to Stock Titan's update alerts. All materials maintain strict editorial standards to support informed decision-making in the rapidly evolving cell therapy landscape.
BioLife Solutions (BLFS) reported significant financial growth for Q3 2021, achieving total revenue of $33.8 million, a 200% increase from Q3 2020. Organic growth was at 37%. The company completed the acquisition of Sexton Biotechnologies, adding over 230 new customers. Despite strong revenue, gross margin decreased to 25% from 52% due to operational challenges and warranty expenses. For 2021, revenue guidance was raised to $115 million to $119 million, representing a growth of 139% to 147%.
On November 4, 2021, BioLife Solutions (Nasdaq: BLFS) announced significant changes in its executive management team. Troy Wichterman, previously Vice President of Finance, has been promoted to Chief Financial Officer, succeeding Roderick de Greef, who now assumes the role of President and Chief Operating Officer after postponing his retirement. Former COO Dusty Tenney has resigned but will consult until year-end. The leadership changes aim to enhance operational efficiency and support ongoing integration efforts following acquisitions.
BioLife Solutions (NASDAQ: BLFS) announced it will release its third quarter 2021 financial results after market close on November 11, 2021. Following the release, a conference call is scheduled for 4:30 PM ET where management will discuss the financial results and provide a business update. Investors can access the call through the company’s Investor Relations page or via phone. BioLife is a leading supplier of bioproduction tools and services for the cell and gene therapy market.
Biolife Solutions (NASDAQ: BLFS) has announced the opening of a new 40,000 square-foot biorepository Center of Excellence in Amsterdam, enhancing its support for cell and gene therapies. The facility features a CAR-T cell storage suite and more than 300 ultra-low temperature freezers, aimed at improving global access to biologic therapies. Already partially contracted to a major pharmaceutical client, the facility is part of BioLife's commitment to innovative infrastructure and biostorage best practices, ensuring the integrity of sensitive biological materials.
BioLife Solutions (NASDAQ: BLFS) announced a collaboration with a top 10 global pharmaceutical company to employ its CryoStor freeze media, evo cold chain management platform, and SciSafe storage services for the launch of a new CAR T-cell therapy. This engagement represents BioLife's strategic push in the cell and gene therapy market. CEO Mike Rice highlighted the company's commitment to supporting bioproduction needs. Currently, CryoStor is used in the manufacturing of several approved therapies and is embedded in additional therapies expected to gain regulatory approval soon.
BioLife Solutions (Nasdaq: BLFS) announced the appointment of Joydeep Goswami to its board of directors, effective October 1, 2021. Goswami, who previously held senior roles at Illumina and Thermo Fisher Scientific, will replace retiring board member Andrew Hinson. The addition aims to bolster the company's strategic planning and partnerships, enhancing shareholder value. CEO Mike Rice expressed excitement about Goswami's expertise in life sciences, anticipating a positive impact on business growth.
BioLife Solutions (Nasdaq: BLFS) announced the retirement of CFO Roderick de Greef, effective December 31, 2021. He will assist in the transition until March 31, 2022. De Greef has been vital to the company for over 20 years, significantly impacting its growth and funding strategies. The company has engaged executive search firm Strawn Arnold to find his successor. CEO Mike Rice expressed gratitude for de Greef's contributions, emphasizing his instrumental role during a period of significant expansion.
BioLife Solutions (Nasdaq: BLFS) has filed a Form S-3 registration statement with the SEC to register approximately 10.7 million shares of restricted common stock. These shares are held by stockholders from acquired companies including Global Cooling, Inc. and Sexton Biotechnologies, and also include shares from Casdin Capital. CEO Mike Rice emphasized the strategic importance of recent acquisitions in a growing market. The filing is in compliance with obligations related to these acquisitions, and no new shares are being issued.
BioLife Solutions (Nasdaq: BLFS) announced the closing of its acquisition of Sexton Biotechnologies on September 1, 2021. This acquisition enhances BioLife’s portfolio with proprietary bioproduction tools, such as closed vials for cell therapy packaging and human platelet lysate media, integral to over 50 ongoing clinical trials. CEO Mike Rice emphasized the strategic significance of this acquisition for expanding revenue and capabilities in the cell and gene therapy market, marking it as BioLife's sixth acquisition in just over two years.
BioLife Solutions (BLFS) announced its inclusion in the S&P SmallCap 600 Index, effective August 30, 2021. This recognition reflects the company’s commitment to enhancing shareholder value through its innovative bioproduction products for cell and gene therapies. The S&P SmallCap 600 Index comprises small-cap companies that meet specific liquidity and financial viability criteria. BioLife's CEO, Mike Rice, emphasized this milestone as a tribute to the team's dedication to customer satisfaction and long-term growth.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
